Brenner, A.K.; Reikvam, H.; Rye, K.P.; Hagen, K.M.; Lavecchia, A.; Bruserud, Ø.
CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors. Molecules 2017, 22, 446.
https://doi.org/10.3390/molecules22030446
AMA Style
Brenner AK, Reikvam H, Rye KP, Hagen KM, Lavecchia A, Bruserud Ø.
CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors. Molecules. 2017; 22(3):446.
https://doi.org/10.3390/molecules22030446
Chicago/Turabian Style
Brenner, Annette K., Håkon Reikvam, Kristin Paulsen Rye, Karen Marie Hagen, Antonio Lavecchia, and Øystein Bruserud.
2017. "CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors" Molecules 22, no. 3: 446.
https://doi.org/10.3390/molecules22030446
APA Style
Brenner, A. K., Reikvam, H., Rye, K. P., Hagen, K. M., Lavecchia, A., & Bruserud, Ø.
(2017). CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors. Molecules, 22(3), 446.
https://doi.org/10.3390/molecules22030446